Gilead and Aelix first teamed up in 2018 for a clinical research collaboration agreement to investigate the vaccine.

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Six years after first allying with Aelix Therapeutics to test the Spanish biotech’s HTI vaccine for HIV, Gilead Sciences has ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Women – especially teen girls and young women living in sub-Saharan Africa – are disproportionately impacted by <a ...

Spanish HIV focused immunotherapies company AELIX Therapeutics, a spin-off of IrisCaixa, has announced the acquisition of its ...

Roughly a year ago, Gilead Sciences revealed that it was laying off about 7% of Kite Pharma’s workforce in a bid to refresh ...

Zacks Research increased their FY2024 earnings per share (EPS) estimates for Gilead Sciences in a note issued to investors on ...

The scope of Gilead Sciences' recent round of layoffs is coming into clearer view with the revelation that the company is ...

Compared to the aggregate P/E ratio of 94.75 in the Biotechnology industry, Gilead Sciences Inc. has a higher P/E ratio of 1002.11. Shareholders might be inclined to think that Gilead Sciences Inc.

Dan O’Day drives Gilead's mission to end HIV worldwide, pioneering treatments like lenacapavir and championing global health ...

On Friday, Gilead Sciences, Inc. (GILD) stock saw a modest uptick, ending the day at $90.19 which represents a slight increase of $0.43 or 0.48% from the prior close of $89.76. The stock opened at $89 ...